News Releases

The following news releases are issued by GlaxoSmithKline Inc. In addition to these resources, you may also find GlaxoSmithKline global news of interest.

December 28, 2006

Landmark Tykerb^TM (Lapatinib Ditosylate) Data Published In The New England Journal Of Medicine -- Study Authors Conclude that Further Investigation Into Earlier Use In The Treatment of HER2 Positive Breast Cancer is Warranted.

December 04, 2006

Landmark study shows Avandia® controls type 2 diabetes longer than most commonly prescribed oral medications in Canada.

November 01, 2006

Older, but not necessarily wiser, when it comes to sexual health -- New Canadian survey results reveal a contradiction when it comes to practicing safe sex among the 30-plus singles crowd

September 15, 2006

Avandia® significantly reduces risk of progression to type 2 diabetes by 62 percent in largest ever diabetes prevention trial

June 05, 2006

New data shows Cervarix^TM, GSK'S HPV 16/18 cervical cancer candidate vaccine, is highly immunogenic and well-tolerated in women over 25 years of age -- First presentation of clinical trial data examining the immune response in women aged 26-55 demonstrate 100 per cent vaccine-induced antibody response against HPV 16/18

June 03, 2006

Pivotal Phase III trial shows that Tykerb^TM (lapatinib ditosylate) tablets nearly doubles time to progression for patients with ErB2 (HER2) positive advanced breast cancer -- Other data presented at ASCO show Tykerb^TM also demonstrates preliminary activity in breast cancer-associated brain metastases and activity in relapsed inflammatory breast cancer

April 26, 2006

Genital Herpes: Managing a Public Health Concern -- New Canadian treatment guidelines provide much-needed direction

April 06, 2006

Cervarix^TM, GSK's Candidate Vaccine for Cervical Cancer, Demonstrated Sustained Efficacy for up to 4.5 Years and Broader Protection Against Cancer-Causing HPV Types -- Follow-up study, published in The Lancet, extends earlier findings of vaccine efficacy and protection against most prevalent cancer-causing types of the human papillomavirus (HPV)

March 30, 2006

GlaxoSmithKline Initiates Human Trial Programme with Two H5N1 Pandemic Flu Vaccines -- GlaxoSmithKline (GSK) announced today the start of an international clinical trial programme to test two pandemic vaccines against the H5N1 strain of the avian influenza virus in humans.

March 14, 2006

ARIXTRA®(fondaparinux sodium) Reduced Risk of Death or Recurrent Heart Attack in Patients with Acute Coronary Syndromes -- GlaxoSmithKline Inc. announced today late-breaking clinical trial results of the OASIS 6 trial that compared its antithrombotic product ARIXTRA® (fondaparinux sodium) to standard therapy in acute coronary syndrome (ACS) patients with ST-elevation MI (STEMI).

March 08, 2006

Leading Ontario Employer launches Innovative Program to Enhance Employee Health -- Ontario's Minister of Health Promotion helps GlaxoSmithKline kick-off 'Your Health Your Way'

February 16, 2006

Major Canadian Type 2 Diabetes Study Shows Significant Improvement in Blood Sugar Control Achievable in Primary-Care Setting -- Patients demonstrate high adherence and achieve aggressive treatment targets.